© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Epzicom

How Well Do Docs Manage Potential Conflicts Between Hep C and HIV Meds?

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
The opening session of CROI 2018 in Boston.

The Best of CROI 2018

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Treating HIV With Just a Boosted Protease Inhibitor and Epivir Works Well

In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.

Government Shutdown May Slow FDA Drug Approvals

The looming threat of a government shutdown on October 1 may spell potential delays in FDA approvals of new drugs.

Viread and Epivir Lower Risk of Hepatitis B Infection in HIV-Positive Gay Men

Viread (tenofovir) and Epivir (lamivudine) lower the risk of infection with hepatitis B among HIV-positive gay men who haven’t been vac...
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.